Nuvista Pharma Ltd
Zoleta is indicated for Breast cancer
Precautions and warnings
Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery.
Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation.
Potentially Fatal: Thromboembolic events.
Plasma levels reduced by tamoxifen.
Premenopausal women and children; hypersensitivity.
Mode of actions
Letrozole competitively binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgen to oestrogen, leading to inhibition of the enzyme and a significant reduction in plasma oestrogen levels.
Dosage & Administration
Adult: PO Adjuvant therapy for post menopausal women with hormone receptor positive early breast cancer; Advanced breast cancer in postmenopausal women 2.5 mg once daily.
Hepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days.
Pregnancy & Lactation
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.